Finally, the U.S
15.3.3 SCOHIA PHARMA, INC
[9] [10] For patients with established cardiovascular disease, SGLT2 inhibitors are generally prioritised for cardiorenal protection, with GLP-1 receptor agonists with proven cardiovascular benefit considered when SGLT2 inhibitors are unsuitable
For many patients who experience fatigue, symptoms may improve as the body adapts to the medication, though the timeline for resolution is highly variable
These findings highlight the importance of targeted therapeutic strategies based on HF phenotypes
Speak with a pharmacist, GP or qualified healthcare professional before using a new supplement if you are pregnant, breastfeeding, taking medication, have a medical condition or are unsure whether it is suitable for you.